Shareholders of SFL Group sell 100% of shares to Veristat
The two former shareholders, Shayesteh Fürst-Ladani und Walter Fürst, have sold 100% of the shares in all SFL group companies with their registered seats in Switzerland (SFL Regulatory Affairs & Scientific Communication und SFL Pharma), Germany (SFL Pharmaceuticals Deutschland), Austria (SFL Regulatory Services), and the UK (SFL Regulatory Affairs Consulting) to US-based clinical research organization (CRO) Veristat.
SFL Group is a consulting firm providing integrated solutions to pharmaceutical, biotech, and Medtech companies in the areas of drug development, regulatory affairs, and clinical trials, as well as combined drug-medicine products.
Walder Wyss acted as lead transaction counsel to the two former shareholders, Shayesteh Fürst-Ladani und Walter Fürst, on the Swiss law aspects of the transaction. The team included partner Stefan Knobloch (corporate/m&a, pictured left), associate Dario Galli (corporate/m&a), and Marina Beeler (junior associate, corporate/m&a).
Niederer Kraft Frey advised Veristat on the acquisition. The NKF team was led by m&a partner Patrik Peyer (pictured right), working with associates Binderiya Gan–Ayush, Michel Herren, junior associates Luisa Egli, Lukas Würgler and Yannik Bleiker (all m&a), counsel Janine Reudt–Demont (life sciences and data protection), partners Adrian Koller (finance) and Nicolas Birkhäuser (antitrust/competition) and associate Annina Fey (employment).
